About VIVUS VIVUS is a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical ...

User engagement in a digital weight-loss service enhanced the effectiveness of GLP-1 receptor agonists and the dual glucose-dependent insulinotropic polypeptide (GIP)-GLP-1 receptor agonists in adults ...

Analysis of a large unsubsidized digital weight-loss service reveals that consistent treatment adherence and active engagement, not access alone, are the key factors separating modest results from ...

Richard Green has worked with the NHS to come with a digitised weight-loss service.

Weight-loss experts reveal their major predictions for 2026, from advanced GLP-1 treatments to AI-driven personalized therapy ...

The pill version of popular weight-loss drug Wegovy became available in the U.S. on Monday, offering patients a daily oral option to the weekly injectable drug.

According to research published by the British Medical Journal (BMJ), those using weight-loss injection drugs could also regain weight almost four times faster than they would after dieting once they ...

Copycats and rivals to Novo Nordisk's blockbuster diabetes and weight-loss treatments Ozempic and Wegovy weigh on the Danish drugmaker's its performance - Copyright ...